Yerushalmi R - Search Results

1

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.

Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R. Lewin R, et al. Among authors: yerushalmi r. Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25. Breast Cancer Res Treat. 2016. PMID: 27225387

2

[Rising CA-125 levels in a patient with ovarian cancer are not always indicative of disease recurrence].

Yerushalmi R, Rakowsky E, Sulkes A. Yerushalmi R, et al. Harefuah. 2002 Apr;141(4):347-8, 410. Harefuah. 2002. PMID: 12017887 Hebrew.

3

Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy.

Koren C, Yerushalmi R, Katz A, Malik H, Sulkes A, Fenig E. Koren C, et al. Among authors: yerushalmi r. Am J Clin Oncol. 2002 Dec;25(6):625-6. doi: 10.1097/00000421-200212000-00020. Am J Clin Oncol. 2002. PMID: 12478013

4

Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil.

Yerushalmi R, Idelevich E, Dror Y, Stemmer SM, Figer A, Sulkes A, Brenner B, Loven D, Dreznik Z, Nudelman I, Shani A, Fenig E. Yerushalmi R, et al. J Surg Oncol. 2006 Jun 1;93(7):529-33. doi: 10.1002/jso.20503. J Surg Oncol. 2006. PMID: 16705722

5

Endobronchial stent for malignant airway obstructions.

Yerushalmi R, Fenig E, Shitrit D, Bendayan D, Sulkes A, Flex D, Kramer MR. Yerushalmi R, et al. Isr Med Assoc J. 2006 Sep;8(9):615-7. Isr Med Assoc J. 2006. PMID: 17058411 Free article.

6

Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?

Yerushalmi R, Sulkes A, Mishaeli M, Neumann A, Dinerman M, Sulkes J, Rizel S, Yarom N, Gutman H, Fenig E. Yerushalmi R, et al. Neoplasma. 2006;53(6):507-10. Neoplasma. 2006. PMID: 17167720

7

Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.

Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, Sulkes A, Gutman H, Catane R, Schachter J. Bar J, et al. Among authors: yerushalmi r. Oncol Rep. 2008 Dec;20(6):1533-8. Oncol Rep. 2008. PMID: 19020738

8

Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study.

Yerushalmi R, Kramer MR, Rizel S, Sulkes A, Gelmon K, Granot T, Neiman V, Stemmer SM. Yerushalmi R, et al. Ann Oncol. 2009 Mar;20(3):437-40. doi: 10.1093/annonc/mdn652. Epub 2009 Jan 12. Ann Oncol. 2009. PMID: 19139179 Free article.

9

Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.

Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, Sulkes A, Stemmer SM. Hendler D, et al. Among authors: yerushalmi r. Am J Clin Oncol. 2011 Dec;34(6):619-24. doi: 10.1097/COC.0b013e3181f94716. Am J Clin Oncol. 2011. PMID: 21217400

10

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Yerushalmi R, et al. Breast Cancer Res Treat. 2012 Feb;132(1):131-42. doi: 10.1007/s10549-011-1529-8. Epub 2011 May 15. Breast Cancer Res Treat. 2012. PMID: 21574055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

219 results

Search Page